Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease

NCT: NCT07572071 · RECRUITING

NCT IDNCT07572071
StatusRECRUITING
Start Date2025-08-01
Completion2030-08-01
SponsorRoyan Institute (OTHER_GOV)
First posted
Last updated

Brief Summary

Dopason is a phase I, open-label, multicenter, single-arm clinical trial designed to evaluate the safety and feasibility of intraputaminal transplantation of human embryonic stem cell-derived dopaminergic progenitor cells (DopaCells) in patients with moderately severe Parkinson's disease.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑